Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling
Background and objective Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various bi...
Saved in:
Published in | Drugs in R&D Vol. 20; no. 4; pp. 343 - 358 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.12.2020
Springer Nature B.V Adis, Springer Healthcare |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and objective
Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors.
Methods
Non-linear mixed-effects modeling was conducted on retrospectively collected data (
n
= 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation–maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter–Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping.
Results
A one-compartment, first-order absorption, Michaelis–Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant.
Conclusions
The linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations. |
---|---|
AbstractList | Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors.BACKGROUND AND OBJECTIVEPhenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors.Non-linear mixed-effects modeling was conducted on retrospectively collected data (n = 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation-maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter-Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping.METHODSNon-linear mixed-effects modeling was conducted on retrospectively collected data (n = 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation-maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter-Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping.A one-compartment, first-order absorption, Michaelis-Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant.RESULTSA one-compartment, first-order absorption, Michaelis-Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant.The linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations.CONCLUSIONSThe linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations. Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors. Non-linear mixed-effects modeling was conducted on retrospectively collected data (n = 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation-maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter-Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping. A one-compartment, first-order absorption, Michaelis-Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant. The linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations. Background and objectivePhenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors.MethodsNon-linear mixed-effects modeling was conducted on retrospectively collected data (n = 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation–maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter–Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping.ResultsA one-compartment, first-order absorption, Michaelis–Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant.ConclusionsThe linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations. Background and objective Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors. Methods Non-linear mixed-effects modeling was conducted on retrospectively collected data ( n = 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation–maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter–Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping. Results A one-compartment, first-order absorption, Michaelis–Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant. Conclusions The linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations. Abstract Background and objective Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are routinely measured in clinical practice. The relationship between free and total phenytoin has been described by various binding models with inconsistent findings. Systematic comparison of these binding models in a single experimental setting is warranted to determine the optimal binding behaviors. Methods Non-linear mixed-effects modeling was conducted on retrospectively collected data (n = 37 adults receiving oral or intravenous phenytoin) using a stochastic approximation expectation–maximization algorithm in MonolixSuite-2019R2. The optimal base structural model was initially developed and utilized to compare four binding models: Winter–Tozer, linear binding, non-linear single-binding site, and non-linear multiple-binding site. Each binding model was subjected to error and covariate modeling. The final model was evaluated using relative standard errors (RSEs), goodness-of-fit plots, visual predictive check, and bootstrapping. Results A one-compartment, first-order absorption, Michaelis–Menten elimination, and linear protein-binding model best described the population pharmacokinetics of free phenytoin at typical clinical concentrations. The non-linear single-binding-site model also adequately described phenytoin binding but generated larger RSEs. The non-linear multiple-binding-site model performed the worst, with no identified covariates. The optimal linear binding model suggested a relatively high binding capacity using a single albumin site. Covariate modeling indicated a positive relationship between albumin concentration and the binding proportionality constant. Conclusions The linear binding model best described the population pharmacokinetics of unbound phenytoin in adult subjects and may be used to improve the prediction of free phenytoin concentrations. |
Author | Cheng, Wendy Ho, Jordan Jun, Heajin Kiang, Tony K. L. Rong, Yan Yih, Catharina |
Author_xml | – sequence: 1 givenname: Heajin surname: Jun fullname: Jun, Heajin organization: College of Pharmacy, Seoul National University, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Katz Group Centre for Pharmacy and Health Research – sequence: 2 givenname: Yan surname: Rong fullname: Rong, Yan organization: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Katz Group Centre for Pharmacy and Health Research – sequence: 3 givenname: Catharina surname: Yih fullname: Yih, Catharina organization: Department of Pharmacy, Vancouver General Hospital – sequence: 4 givenname: Jordan surname: Ho fullname: Ho, Jordan organization: Department of Pharmacy, Vancouver General Hospital – sequence: 5 givenname: Wendy surname: Cheng fullname: Cheng, Wendy organization: Department of Pharmacy, Vancouver General Hospital – sequence: 6 givenname: Tony K. L. orcidid: 0000-0003-4548-9746 surname: Kiang fullname: Kiang, Tony K. L. email: tkiang@ualberta.ca organization: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Katz Group Centre for Pharmacy and Health Research |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33026608$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uk1v1DAQjVAR_YA_wAFF4sIl4I_Edi5IZdVCpS3sgT1bjj3e9ZK1FztBlP_Cf8WbLYX2UMmSrZn33sx43mlx5IOHoniJ0VuMEH-XakSYqBBBFUKU0Io8KU4w5m3FWoSPpnddNUKw4-I0pQ1CCFMmnhXHlGYmQ-Kk-D0L252KLgWfymDLyzDGchHDAM5XH5w3zq_K62CgT-VsraLSA0T3ax8d1lAucmirdPjmPAxOTxJL34XRm5wDfzME58t8zs3YD-VCDQ78kMpl2it8Dr6aZ6aK5bX7Caa6sBZ0Tk8FM-J58dSqPsGL2_usWF5efJ19quZfPl7NzueVbmo0VHkUCkBxzWjXMowp6UA31hJeQwMdbZpaW94YbVWjmak7Ay3TCiwXQDKInhVXB10T1EbuotuqeCODcnIKhLiSKub5epC01YprZCznrKaatS1HFLVGaAMGrM1a7w9au7HbgtF53qj6e6L3M96t5Sr8kJy1uMYsC7y5FYjh-whpkFuXNPS98hDGJEldt1hgJvbQ1w-gm7w_n79KUkJoK7hAPKNe_d_RXSt_XZAB5ADQMaQUwd5BMJJ7q8mD1WS2mpysJkkmiQck7Ya837CfyvWPU-mBmnIdv4L4r-1HWH8AA1vrNQ |
CitedBy_id | crossref_primary_10_1111_pan_14631 crossref_primary_10_3390_pharmaceutics14102226 crossref_primary_10_1007_s40262_023_01280_0 crossref_primary_10_1080_17425255_2025_2470792 crossref_primary_10_3390_pharmaceutics13081208 |
Cites_doi | 10.2165/11595650-000000000-00000 10.1001/archneur.1974.00490410037002 10.1111/j.1365-2125.1991.tb05499.x 10.1248/bpb.19.444 10.4103/jrpp.JRPP_17_58 10.1111/j.1742-7843.2006.pto_309.x 10.1038/sj.clpt.6100241 10.1002/jcph.417 10.1111/bcp.14053 10.1177/0883073813486294 10.5858/arpa.2014-0464-CP 10.1097/00007691-199802000-00011 10.1016/0006-291X(91)91680-B 10.1002/phar.2273 10.1007/BF03261932 10.1097/FTD.0000000000000546 10.1038/psp.2013.14 10.1016/j.bbagen.2013.03.026 10.1111/j.1528-1167.2012.03671.x 10.1007/s13318-018-0525-3 10.1159/000500314 10.1046/j.1365-2885.2002.00442.x 10.1046/j.1468-1331.1999.630331.x 10.1016/j.cbi.2016.04.040 10.1016/j.xphs.2018.03.023 10.2165/00003088-199018010-00003 10.1684/epd.2014.0714 10.1177/106002809703100301 10.1016/j.jchromb.2004.06.012 10.1345/aph.1R651 10.1177/2042098611411127 10.1177/0091270009343006 10.1007/s40262-019-00771-3 10.1111/j.1528-1157.1959.tb04274.x 10.1097/01.ftd.0000184161.52573.0e 10.3390/nu6115280 10.1016/j.arcmed.2004.11.006 10.1038/clpt.1981.10 10.2165/00003088-198308040-00006 10.1001/archneur.1964.00460240074010 10.4103/0975-8453.59514 10.1159/000168708 10.1186/1472-6947-12-7 10.1007/BF03261928 10.1007/BF03189395 10.1007/s00228-014-1709-7 10.1111/j.1365-2710.1994.tb00681.x 10.1038/clpt.2014.159 10.1007/s00228-010-0817-2 10.2165/00003088-197904030-00001 10.1016/S0920-1211(99)00017-0 10.1007/s00228-008-0553-z 10.1177/1060028017707541 10.7326/0003-4819-150-9-200905050-00006 10.1002/cpt1976192135 10.1159/000184949 10.1097/FTD.0000000000000354 10.1111/j.1468-1331.2011.03361.x 10.9740/mhc.2015.01.008 10.5698/1535-7597.18.4s1.1 10.1517/17425255.2015.1111871 |
ContentType | Journal Article |
Copyright | The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1007/s40268-020-00323-2 |
DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1179-6901 |
EndPage | 358 |
ExternalDocumentID | oai_doaj_org_article_39ca7c0df77643c69970309d8cdedeff PMC7691416 33026608 10_1007_s40268_020_00323_2 |
Genre | Journal Article Comparative Study |
GrantInformation_xml | – fundername: Mitacs Globalink grantid: #FR41232; #FR41232 – fundername: National Research Foundation of Korea grantid: #2019K1A3A1A73079569 – fundername: Mitacs Globalink grantid: #FR41232 – fundername: ; grantid: #FR41232; #FR41232 – fundername: ; grantid: #2019K1A3A1A73079569 |
GroupedDBID | --- -A0 .XZ 0R~ 29G 2JY 36B 3V. 4.4 53G 5GY 6I2 7X7 88E 8FI 8FJ 8R4 8R5 AAKAS AAKKN ABDBF ABEEZ ABUWG ABWHX ACACY ACGFS ACUHS ACULB ADBBV ADRAZ ADZCM AEYRQ AFGXO AFKRA AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF A~4 BAPOH BAWUL BCNDV BENPR BPHCQ BVXVI BYPQX C24 C6C CAG CCPQU COF CS3 DIK DU5 EAP EBC EBS EJD EMB EMK EMOBN EPL ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IEA IHR INH INR ITC KQ8 M1P M48 MK0 O9- OAC OB2 OK1 OVD PQQKQ PROAC PSQYO Q2X R2J RNS RPM RSV RZALA SISQX SOJ SV3 TEORI TUS UKHRP W1D YFH ~JE AAYXX ADGHP CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c540t-6603ee31463b961132bec5ff274e5eb3554cf75dcfa5c6d4bde96caef78e22743 |
IEDL.DBID | 7X7 |
ISSN | 1174-5886 1179-6901 |
IngestDate | Wed Aug 27 01:29:13 EDT 2025 Thu Aug 21 13:58:38 EDT 2025 Mon Jul 21 10:43:43 EDT 2025 Sat Aug 23 12:43:37 EDT 2025 Thu Apr 03 06:57:31 EDT 2025 Tue Jul 01 01:30:36 EDT 2025 Thu Apr 24 22:56:36 EDT 2025 Fri Feb 21 02:37:02 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c540t-6603ee31463b961132bec5ff274e5eb3554cf75dcfa5c6d4bde96caef78e22743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
ORCID | 0000-0003-4548-9746 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1007/s40268-020-00323-2 |
PMID | 33026608 |
PQID | 3223987807 |
PQPubID | 2034452 |
PageCount | 16 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_39ca7c0df77643c69970309d8cdedeff pubmedcentral_primary_oai_pubmedcentral_nih_gov_7691416 proquest_miscellaneous_2449181686 proquest_journals_3223987807 pubmed_primary_33026608 crossref_primary_10_1007_s40268_020_00323_2 crossref_citationtrail_10_1007_s40268_020_00323_2 springer_journals_10_1007_s40268_020_00323_2 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-12-01 |
PublicationDateYYYYMMDD | 2020-12-01 |
PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: New Zealand – name: Auckland |
PublicationTitle | Drugs in R&D |
PublicationTitleAbbrev | Drugs R D |
PublicationTitleAlternate | Drugs R D |
PublicationYear | 2020 |
Publisher | Springer International Publishing Springer Nature B.V Adis, Springer Healthcare |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V – name: Adis, Springer Healthcare |
References | Kesavan, Narayan, Adithan (CR74) 2010; 66 ter Heine, van Maarseveen, van der Westerlaken, Braun, Koudijs, ten Berg, Malingre (CR27) 2014; 29 Alimardani, Sadrai, Masoumi, Salari, Najafi, Eftekhar, Mojtahedzadeh (CR56) 2017; 6 Abduljabbar, Al-Khamis, Ogunniyi, Daif, Al-Yamani (CR55) 1999; 6 Buchthal, Svensmark (CR14) 1960; 1 Patsalos, Spencer, Berry (CR37) 2018; 40 Dasgupta, Malik (CR64) 1994; 14 Zaccara, Perucca (CR67) 2014; 16 Odani, Hashimoto, Takayanagi, Otsuki, Koue, Takano, Yasuhara, Hattori, Furusho, Inui (CR53) 1996; 19 Kozelka, Hine (CR9) 1943; 77 CR34 Ebadi, Mazurak (CR58) 2014; 6 Anderson, Pak, Doane, Griffy, Temkin, Wilensky, Winn (CR21) 1997; 31 Marvanova (CR12) 2016; 6 CR73 Brodie, Mintzer, Pack, Gidal, Vecht, Schmidt (CR11) 2013; 54 CR70 Krasowski, Penrod (CR18) 2012; 12 Aarons, Ahmed, Deleu (CR44) 2005; 36 Hennessy, Leonard, Freeman, Metlay, Chu, Strom, Bilker (CR76) 2009; 49 Montgomery, Chou, McPharlin, Baird, Anderson (CR48) 2019; 39 Miller, Rheeders, Klein, Suchet (CR50) 1987; 72 Kutt, Winters, Kokenge, McDowell (CR15) 1964; 11 Lecomte, Zini, d'Athis, Tillement (CR69) 1979; 4 CR4 CR3 ter Heine, Kane, Huitema, Krasowski, van Maarseveen (CR25) 2019; 85 Kragh-Hansen, Minchiotti, Galliano, Peters (CR77) 2013; 1830 Ismail, Rahman, Chand (CR54) 1994; 19 Weber, Leonard, Zemel (CR59) 2012; 10 CR43 French, Gazzola (CR1) 2011; 2 Chetty, Miller, Seymour (CR17) 1998; 20 Musteata (CR32) 2012; 51 Rong, Mayo, Ensom, Kiang (CR35) 2019; 58 Leonard, Knott, Rankin, Robinson, Melnick (CR66) 1981; 29 Rettie, Haining, Bajpai, Levy (CR71) 1999; 35 Cheng, Kiang, Bring, Ensom (CR22) 2016; 69 Gugler, Manion, Azarnoff (CR45) 1976; 19 Karlsson, Savic (CR47) 2007; 82 Deitchman, Singh, Derendorf (CR60) 2018; 107 Hennig, Norris, Tu, van Breda, Riney, Foster, Lister, Charles (CR24) 2015; 55 Rong, Mayo, Ensom, Kiang (CR36) 2019; 44 Gerber, Wagner (CR10) 1972; 3 Depondt, Godard, Espel, Da Cruz, Lienard, Pandolfo (CR75) 2011; 18 Sellers, Koch-Weser, Rosenoer, Oratz, Rothschild (CR61) 1977 Sherwin, Kiang, Spigarelli, Ensom (CR40) 2012; 51 Mould, Upton (CR46) 2013; 2 Chen, Ohnmacht, Hage (CR30) 2004; 809 Howanitz, Darcy, Meier, Bashleben (CR42) 2015; 139 Doecke, Veronese, Pond, Miners, Birkett, Sansom, McManus (CR8) 1991; 31 Chavda, Patel, Anand (CR57) 2010; 1 Barnes, Rowland, Polasek, Miners (CR65) 2014; 70 CR16 CR13 Bajpai, Roskos, Shen, Levy (CR6) 1996; 24 Tozer, Winter, Evans, Schentag, Jusko (CR19) 1992 Alqahtani, Alzaidi, Alotaibi, Alsultan (CR52) 2019; 104 Richens (CR5) 1979; 4 Kiang, Sherwin, Spigarelli, Ensom (CR39) 2012; 51 Mabuchi, Nakahashi (CR63) 1988; 48 Toutain, Bousquet-Melou (CR31) 2002; 25 Joerger, Huitema, Boogerd, van der Sande, Schellens, Beijnen (CR26) 2006; 99 Nation, Evans, Milne (CR68) 1990; 18 Abou-Khalil (CR2) 2019; 25 CR29 CR28 Kane, Bress, Tesoro (CR23) 2013; 47 Winter, Murphy (CR38) 2017 Chen, Wang, Zhu, Xiong, Sun, Dai, Cai, Hu (CR72) 2016; 253 Verbeeck (CR62) 2008; 64 Charles, Norris, Xiao, Hague (CR33) 2006; 28 Grasela, Sheiner, Rambeck, Boenigk, Dunlop, Mullen, Wadsworth, Richens, Ishizaki, Chiba, Miura, Minagawa, Blain, Mucklow, Bacon, Rawlins (CR49) 1983; 8 Veronese, Mackenzie, Doecke, McManus, Miners, Birkett (CR7) 1991; 175 Appendix, Chisholm-Burns, Wells, Schwinghammer, Malone, Kolesar, Dipiro (CR41) 2013 Soriano, Tesoro, Kane (CR20) 2017; 51 Ku, Wu, Greenberg, Hill, Gonzalez, Hornik, Berezny, Guptill, Jiang, Zheng, Cohen-Wolkowiez, Melloni (CR51) 2016; 38 FL Kozelka (323_CR9) 1943; 77 PL Toutain (323_CR31) 2002; 25 R Ismail (323_CR54) 1994; 19 323_CR73 A Odani (323_CR53) 1996; 19 S Hennessy (323_CR76) 2009; 49 323_CR70 N Gerber (323_CR10) 1972; 3 MD Krasowski (323_CR18) 2012; 12 R Miller (323_CR50) 1987; 72 M Chetty (323_CR17) 1998; 20 FM Musteata (323_CR32) 2012; 51 323_CR34 R Kesavan (323_CR74) 2010; 66 323_CR29 323_CR28 R ter Heine (323_CR25) 2019; 85 MJ Brodie (323_CR11) 2013; 54 S Alqahtani (323_CR52) 2019; 104 CMT Sherwin (323_CR40) 2012; 51 CJ Doecke (323_CR8) 1991; 31 TN Tozer (323_CR19) 1992 A Dasgupta (323_CR64) 1994; 14 BW Abou-Khalil (323_CR2) 2019; 25 R Gugler (323_CR45) 1976; 19 R ter Heine (323_CR27) 2014; 29 DR Weber (323_CR59) 2012; 10 323_CR4 323_CR3 J Chen (323_CR30) 2004; 809 AN Deitchman (323_CR60) 2018; 107 RK Verbeeck (323_CR62) 2008; 64 M Lecomte (323_CR69) 1979; 4 W Cheng (323_CR22) 2016; 69 M Marvanova (323_CR12) 2016; 6 EM Sellers (323_CR61) 1977 A Richens (323_CR5) 1979; 4 VV Soriano (323_CR20) 2017; 51 ME Veronese (323_CR7) 1991; 175 G Zaccara (323_CR67) 2014; 16 F Buchthal (323_CR14) 1960; 1 DR Mould (323_CR46) 2013; 2 323_CR13 JA French (323_CR1) 2011; 2 323_CR16 MO Karlsson (323_CR47) 2007; 82 TKL Kiang (323_CR39) 2012; 51 LG Chen (323_CR72) 2016; 253 SP Kane (323_CR23) 2013; 47 M Ebadi (323_CR58) 2014; 6 TH Grasela (323_CR49) 1983; 8 M Abduljabbar (323_CR55) 1999; 6 HV Chavda (323_CR57) 2010; 1 C Depondt (323_CR75) 2011; 18 PJ Howanitz (323_CR42) 2015; 139 S Alimardani (323_CR56) 2017; 6 KJ Barnes (323_CR65) 2014; 70 MC Montgomery (323_CR48) 2019; 39 H Mabuchi (323_CR63) 1988; 48 LC Ku (323_CR51) 2016; 38 Y Rong (323_CR36) 2019; 44 PN Patsalos (323_CR37) 2018; 40 GD Anderson (323_CR21) 1997; 31 RL Nation (323_CR68) 1990; 18 H Kutt (323_CR15) 1964; 11 S Hennig (323_CR24) 2015; 55 Y Rong (323_CR35) 2019; 58 AE Rettie (323_CR71) 1999; 35 U Kragh-Hansen (323_CR77) 2013; 1830 M Bajpai (323_CR6) 1996; 24 L Aarons (323_CR44) 2005; 36 323_CR43 ME Winter (323_CR38) 2017 RF Leonard (323_CR66) 1981; 29 B Charles (323_CR33) 2006; 28 M Joerger (323_CR26) 2006; 99 B Appendix (323_CR41) 2013 |
References_xml | – ident: CR70 – volume: 8 start-page: 355 year: 1983 end-page: 364 ident: CR49 article-title: Steady-state pharmacokinetics of phenytoin from routinely collected patient data publication-title: Clin Pharmacokinet – volume: 175 start-page: 1112 year: 1991 end-page: 1118 ident: CR7 article-title: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9 publication-title: Biochem Biophys Res Commun – volume: 6 start-page: 5280 year: 2014 end-page: 5297 ident: CR58 article-title: Evidence and mechanisms of fat depletion in cancer publication-title: Nutrients – volume: 4 start-page: 23 year: 1979 end-page: 28 ident: CR69 article-title: Phenytoin binding to human albumin publication-title: Eur J Drug Metab Pharmacokinet – volume: 44 start-page: 409 year: 2019 end-page: 422 ident: CR36 article-title: Population pharmacokinetic analysis of immediate-release oral tacrolimus co-administered with mycophenolate mofetil in corticosteroid-free adult kidney transplant recipients publication-title: Eur J Drug Metab Pharmacokinet – volume: 139 start-page: 1108 year: 2015 end-page: 1114 ident: CR42 article-title: Assessing clinical laboratory quality: a College of American Pathologists Q-Probes study of prothrombin time INR structures, processes, and outcomes in 98 laboratories publication-title: Arch Pathol Lab Med – volume: 14 start-page: 162 year: 1994 end-page: 168 ident: CR64 article-title: Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins publication-title: Am J Nephrol – ident: CR4 – volume: 38 start-page: 728 year: 2016 end-page: 737 ident: CR51 article-title: Use of therapeutic drug monitoring, electronic health record data, and pharmacokinetic modeling to determine the therapeutic index of phenytoin and lamotrigine publication-title: Ther Drug Monit – ident: CR16 – volume: 253 start-page: 93 year: 2016 end-page: 99 ident: CR72 article-title: In vitro metabolism of phenytoin in 36 CYP2C9 variants found in the Chinese population publication-title: Chem Biol Interact – volume: 31 start-page: 279 year: 1997 end-page: 284 ident: CR21 article-title: Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia publication-title: Ann Pharmacother – volume: 107 start-page: 1754 year: 2018 end-page: 1760 ident: CR60 article-title: Nonlinear protein binding: not what you think publication-title: J Pharm Sci – volume: 29 start-page: 803 year: 2014 end-page: 810 ident: CR27 article-title: The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children publication-title: J Child Neurol – volume: 29 start-page: 56 year: 1981 end-page: 60 ident: CR66 article-title: Phenytoin-salicylate interaction publication-title: Clin Pharmacol Ther – start-page: 1 year: 1992 end-page: 44 ident: CR19 article-title: Phenytoin publication-title: Applied pharmacokinetics: principles of therapeutic drug monitoring – ident: CR29 – volume: 19 start-page: 444 year: 1996 end-page: 448 ident: CR53 article-title: Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model publication-title: Biol Pharm Bull – volume: 1830 start-page: 5405 year: 2013 end-page: 5417 ident: CR77 article-title: Human serum albumin isoforms: genetic and molecular aspects and functional consequences publication-title: Biochim Biophys Acta – volume: 6 start-page: 8 year: 2016 end-page: 20 ident: CR12 article-title: Pharmacokinetic characteristics of antiepileptic drugs (AEDs) publication-title: Ment Health Clin – volume: 51 start-page: 515 year: 2012 end-page: 525 ident: CR39 article-title: Fundamentals of population pharmacokinetic modelling: modelling and software publication-title: Clin Pharmacokinet – volume: 19 start-page: 135 year: 1976 end-page: 142 ident: CR45 article-title: Phenytoin: pharmacokinetics and bioavailability publication-title: Clin Pharmacol Ther – volume: 31 start-page: 125 year: 1991 end-page: 130 ident: CR8 article-title: Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes publication-title: Br J Clin Pharmacol – volume: 6 start-page: 331 year: 1999 end-page: 334 ident: CR55 article-title: Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters publication-title: Eur J Neurol – volume: 48 start-page: 310 year: 1988 end-page: 314 ident: CR63 article-title: A major inhibitor of phenytoin binding to serum protein in uremia publication-title: Nephron – volume: 809 start-page: 137 year: 2004 end-page: 145 ident: CR30 article-title: Studies of phenytoin binding to human serum albumin by high-performance affinity chromatography publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – start-page: 159 year: 1977 end-page: 182 ident: CR61 article-title: Clinical implications of drug-albumin interaction publication-title: Albumin: structure, function and uses – volume: 69 start-page: 269 year: 2016 end-page: 279 ident: CR22 article-title: Predictive performance of the Winter-Tozer and derivative equations for estimating free phenytoin concentration publication-title: Can J Hosp Pharm – volume: 10 start-page: 130 year: 2012 end-page: 139 ident: CR59 article-title: Body composition analysis in the pediatric population publication-title: Pediatr Endocrinol Rev – volume: 51 start-page: 55 year: 2012 end-page: 68 ident: CR32 article-title: Calculation of normalized drug concentrations in the presence of altered plasma protein binding publication-title: Clin Pharmacokinet – volume: 66 start-page: 689 year: 2010 end-page: 696 ident: CR74 article-title: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients publication-title: Eur J Clin Pharmacol – volume: 18 start-page: 1159 year: 2011 end-page: 1164 ident: CR75 article-title: A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity publication-title: Eur J Neurol – volume: 2 start-page: e38 year: 2013 ident: CR46 article-title: Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 77 start-page: 175 year: 1943 end-page: 179 ident: CR9 article-title: Degradation products of dilantin publication-title: J Pharmacol Exp Ther – volume: 39 start-page: 756 year: 2019 end-page: 766 ident: CR48 article-title: Predicting unbound phenytoin concentrations: effects of albumin concentration and kidney dysfunction publication-title: Pharmacotherapy – volume: 2 start-page: 141 year: 2011 end-page: 158 ident: CR1 article-title: New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? publication-title: Ther Adv Drug Saf – volume: 3 start-page: 455 year: 1972 end-page: 466 ident: CR10 article-title: Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation publication-title: Res Commun Chem Pathol Pharmacol – volume: 49 start-page: 1483 year: 2009 end-page: 1487 ident: CR76 article-title: CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity publication-title: J Clin Pharmacol – volume: 16 start-page: 409 year: 2014 end-page: 431 ident: CR67 article-title: Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs publication-title: Epileptic Disord – volume: 12 start-page: 7 year: 2012 ident: CR18 article-title: Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations publication-title: BMC Med Inform Decis Mak – volume: 24 start-page: 1401 year: 1996 end-page: 1403 ident: CR6 article-title: Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite publication-title: Drug Metab Dispos – volume: 51 start-page: 669 year: 2017 end-page: 674 ident: CR20 article-title: Characterization of free phenytoin concentrations in end-stage renal disease using the Winter-Tozer equation publication-title: Ann Pharmacother – volume: 58 start-page: 1483 year: 2019 end-page: 1495 ident: CR35 article-title: Population pharmacokinetics of mycophenolic acid co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients publication-title: Clin Pharmacokinet – volume: 82 start-page: 17 year: 2007 end-page: 20 ident: CR47 article-title: Diagnosing model diagnostics publication-title: Clin Pharmacol Ther – ident: CR43 – volume: 54 start-page: 11 year: 2013 end-page: 27 ident: CR11 article-title: Enzyme induction with antiepileptic drugs: cause for concern? publication-title: Epilepsia – volume: 64 start-page: 1147 year: 2008 end-page: 1161 ident: CR62 article-title: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction publication-title: Eur J Clin Pharmacol – volume: 70 start-page: 1097 year: 2014 end-page: 1106 ident: CR65 article-title: Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins publication-title: Eur J Clin Pharmacol – volume: 11 start-page: 642 year: 1964 end-page: 648 ident: CR15 article-title: Diphenylhydantoin metabolism, blood levels, and toxicity publication-title: Arch Neurol – volume: 55 start-page: 355 year: 2015 end-page: 364 ident: CR24 article-title: Population pharmacokinetics of phenytoin in critically ill children publication-title: J Clin Pharmacol – volume: 72 start-page: 188 year: 1987 end-page: 190 ident: CR50 article-title: Population pharmacokinetics of phenytoin in South African black patients publication-title: S Afr Med J – volume: 25 start-page: 508 year: 2019 end-page: 536 ident: CR2 article-title: Update on antiepileptic drugs 2019 publication-title: Continuum (Minneap Minn) – volume: 51 start-page: 573 year: 2012 end-page: 590 ident: CR40 article-title: Fundamentals of population pharmacokinetic modelling: validation methods publication-title: Clin Pharmacokinet – volume: 19 start-page: 245 year: 1994 end-page: 248 ident: CR54 article-title: Pharmacokinetics of phenytoin in routine clinic patients in Malaysia publication-title: J Clin Pharm Ther – volume: 20 start-page: 60 year: 1998 end-page: 62 ident: CR17 article-title: Phenytoin auto-induction publication-title: Ther Drug Monit – volume: 99 start-page: 133 year: 2006 end-page: 140 ident: CR26 article-title: Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients publication-title: Basic Clin Pharmacol Toxicol – volume: 4 start-page: 153 year: 1979 end-page: 169 ident: CR5 article-title: Clinical pharmacokinetics of phenytoin publication-title: Clin Pharmacokinet – volume: 25 start-page: 460 year: 2002 end-page: 463 ident: CR31 article-title: Free drug fraction vs free drug concentration: a matter of frequent confusion publication-title: J Vet Pharmacol Ther – volume: 6 start-page: 217 year: 2017 end-page: 222 ident: CR56 article-title: Pharmacokinetic behavior of phenytoin in head trauma and cerebrovascular accident patients in an Iranian population publication-title: J Res Pharm Pract – ident: CR73 – ident: CR3 – volume: 104 start-page: 60 year: 2019 end-page: 66 ident: CR52 article-title: Estimation of phenytoin pharmacokinetic parameters in Saudi epileptic patients publication-title: Pharmacology – ident: CR13 – volume: 40 start-page: 526 year: 2018 end-page: 548 ident: CR37 article-title: Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update publication-title: Ther Drug Monit – start-page: 333 year: 2017 end-page: 350 ident: CR38 article-title: Phenytoin and fosphenytoin publication-title: Clinical pharmacokinetics – volume: 28 start-page: 67 year: 2006 end-page: 72 ident: CR33 article-title: Population pharmacokinetics of metformin in late pregnancy publication-title: Ther Drug Monit – ident: CR34 – start-page: 1813 year: 2013 end-page: 1818 ident: CR41 article-title: Common Laboratory Tests publication-title: Pharmacotherapy: principles and practice – volume: 1 start-page: 62 year: 2010 end-page: 69 ident: CR57 article-title: Biopharmaceutics classification system publication-title: Sys Rev Pharm – volume: 35 start-page: 253 year: 1999 end-page: 255 ident: CR71 article-title: A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin publication-title: Epilepsy Res – ident: CR28 – volume: 36 start-page: 49 year: 2005 end-page: 53 ident: CR44 article-title: Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients publication-title: Arch Med Res – volume: 1 start-page: 373 year: 1960 end-page: 384 ident: CR14 article-title: Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy publication-title: Epilepsia – volume: 47 start-page: 628 year: 2013 end-page: 636 ident: CR23 article-title: Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation publication-title: Ann Pharmacother – volume: 18 start-page: 37 year: 1990 end-page: 60 ident: CR68 article-title: Pharmacokinetic drug interactions with phenytoin (Part I) publication-title: Clin Pharmacokinet – volume: 85 start-page: 2360 year: 2019 end-page: 2368 ident: CR25 article-title: Nonlinear protein binding of phenytoin in clinical practice: development and validation of a mechanistic prediction model publication-title: Br J Clin Pharmacol – ident: 323_CR29 – volume: 51 start-page: 55 year: 2012 ident: 323_CR32 publication-title: Clin Pharmacokinet doi: 10.2165/11595650-000000000-00000 – ident: 323_CR16 doi: 10.1001/archneur.1974.00490410037002 – volume: 31 start-page: 125 year: 1991 ident: 323_CR8 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1991.tb05499.x – volume: 19 start-page: 444 year: 1996 ident: 323_CR53 publication-title: Biol Pharm Bull doi: 10.1248/bpb.19.444 – volume: 6 start-page: 217 year: 2017 ident: 323_CR56 publication-title: J Res Pharm Pract doi: 10.4103/jrpp.JRPP_17_58 – volume: 99 start-page: 133 year: 2006 ident: 323_CR26 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2006.pto_309.x – volume: 69 start-page: 269 year: 2016 ident: 323_CR22 publication-title: Can J Hosp Pharm – volume: 82 start-page: 17 year: 2007 ident: 323_CR47 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100241 – volume: 72 start-page: 188 year: 1987 ident: 323_CR50 publication-title: S Afr Med J – volume: 55 start-page: 355 year: 2015 ident: 323_CR24 publication-title: J Clin Pharmacol doi: 10.1002/jcph.417 – volume: 85 start-page: 2360 year: 2019 ident: 323_CR25 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14053 – ident: 323_CR3 – volume: 29 start-page: 803 year: 2014 ident: 323_CR27 publication-title: J Child Neurol doi: 10.1177/0883073813486294 – volume: 139 start-page: 1108 year: 2015 ident: 323_CR42 publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2014-0464-CP – volume: 20 start-page: 60 year: 1998 ident: 323_CR17 publication-title: Ther Drug Monit doi: 10.1097/00007691-199802000-00011 – volume: 175 start-page: 1112 year: 1991 ident: 323_CR7 publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(91)91680-B – volume: 39 start-page: 756 year: 2019 ident: 323_CR48 publication-title: Pharmacotherapy doi: 10.1002/phar.2273 – volume: 51 start-page: 573 year: 2012 ident: 323_CR40 publication-title: Clin Pharmacokinet doi: 10.1007/BF03261932 – volume: 40 start-page: 526 year: 2018 ident: 323_CR37 publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000546 – volume: 2 start-page: e38 year: 2013 ident: 323_CR46 publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1038/psp.2013.14 – volume: 1830 start-page: 5405 year: 2013 ident: 323_CR77 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbagen.2013.03.026 – volume: 54 start-page: 11 year: 2013 ident: 323_CR11 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2012.03671.x – volume: 44 start-page: 409 year: 2019 ident: 323_CR36 publication-title: Eur J Drug Metab Pharmacokinet doi: 10.1007/s13318-018-0525-3 – volume: 104 start-page: 60 year: 2019 ident: 323_CR52 publication-title: Pharmacology doi: 10.1159/000500314 – volume: 25 start-page: 460 year: 2002 ident: 323_CR31 publication-title: J Vet Pharmacol Ther doi: 10.1046/j.1365-2885.2002.00442.x – volume: 6 start-page: 331 year: 1999 ident: 323_CR55 publication-title: Eur J Neurol doi: 10.1046/j.1468-1331.1999.630331.x – volume: 253 start-page: 93 year: 2016 ident: 323_CR72 publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2016.04.040 – ident: 323_CR4 – volume: 107 start-page: 1754 year: 2018 ident: 323_CR60 publication-title: J Pharm Sci doi: 10.1016/j.xphs.2018.03.023 – start-page: 1 volume-title: Applied pharmacokinetics: principles of therapeutic drug monitoring year: 1992 ident: 323_CR19 – volume: 18 start-page: 37 year: 1990 ident: 323_CR68 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199018010-00003 – volume: 25 start-page: 508 year: 2019 ident: 323_CR2 publication-title: Continuum (Minneap Minn) – volume: 10 start-page: 130 year: 2012 ident: 323_CR59 publication-title: Pediatr Endocrinol Rev – volume: 16 start-page: 409 year: 2014 ident: 323_CR67 publication-title: Epileptic Disord doi: 10.1684/epd.2014.0714 – volume: 31 start-page: 279 year: 1997 ident: 323_CR21 publication-title: Ann Pharmacother doi: 10.1177/106002809703100301 – volume: 809 start-page: 137 year: 2004 ident: 323_CR30 publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2004.06.012 – volume: 47 start-page: 628 year: 2013 ident: 323_CR23 publication-title: Ann Pharmacother doi: 10.1345/aph.1R651 – volume: 2 start-page: 141 year: 2011 ident: 323_CR1 publication-title: Ther Adv Drug Saf doi: 10.1177/2042098611411127 – volume: 49 start-page: 1483 year: 2009 ident: 323_CR76 publication-title: J Clin Pharmacol doi: 10.1177/0091270009343006 – volume: 58 start-page: 1483 year: 2019 ident: 323_CR35 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-019-00771-3 – volume: 1 start-page: 373 year: 1960 ident: 323_CR14 publication-title: Epilepsia doi: 10.1111/j.1528-1157.1959.tb04274.x – volume: 28 start-page: 67 year: 2006 ident: 323_CR33 publication-title: Ther Drug Monit doi: 10.1097/01.ftd.0000184161.52573.0e – volume: 6 start-page: 5280 year: 2014 ident: 323_CR58 publication-title: Nutrients doi: 10.3390/nu6115280 – volume: 36 start-page: 49 year: 2005 ident: 323_CR44 publication-title: Arch Med Res doi: 10.1016/j.arcmed.2004.11.006 – volume: 29 start-page: 56 year: 1981 ident: 323_CR66 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1981.10 – volume: 8 start-page: 355 year: 1983 ident: 323_CR49 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-198308040-00006 – volume: 77 start-page: 175 year: 1943 ident: 323_CR9 publication-title: J Pharmacol Exp Ther – volume: 11 start-page: 642 year: 1964 ident: 323_CR15 publication-title: Arch Neurol doi: 10.1001/archneur.1964.00460240074010 – volume: 1 start-page: 62 year: 2010 ident: 323_CR57 publication-title: Sys Rev Pharm doi: 10.4103/0975-8453.59514 – volume: 14 start-page: 162 year: 1994 ident: 323_CR64 publication-title: Am J Nephrol doi: 10.1159/000168708 – volume: 12 start-page: 7 year: 2012 ident: 323_CR18 publication-title: BMC Med Inform Decis Mak doi: 10.1186/1472-6947-12-7 – volume: 51 start-page: 515 year: 2012 ident: 323_CR39 publication-title: Clin Pharmacokinet doi: 10.1007/BF03261928 – volume: 4 start-page: 23 year: 1979 ident: 323_CR69 publication-title: Eur J Drug Metab Pharmacokinet doi: 10.1007/BF03189395 – start-page: 1813 volume-title: Pharmacotherapy: principles and practice year: 2013 ident: 323_CR41 – volume: 70 start-page: 1097 year: 2014 ident: 323_CR65 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-014-1709-7 – volume: 19 start-page: 245 year: 1994 ident: 323_CR54 publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.1994.tb00681.x – start-page: 159 volume-title: Albumin: structure, function and uses year: 1977 ident: 323_CR61 – ident: 323_CR73 doi: 10.1038/clpt.2014.159 – volume: 66 start-page: 689 year: 2010 ident: 323_CR74 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-010-0817-2 – volume: 4 start-page: 153 year: 1979 ident: 323_CR5 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-197904030-00001 – volume: 35 start-page: 253 year: 1999 ident: 323_CR71 publication-title: Epilepsy Res doi: 10.1016/S0920-1211(99)00017-0 – ident: 323_CR34 – ident: 323_CR13 – volume: 24 start-page: 1401 year: 1996 ident: 323_CR6 publication-title: Drug Metab Dispos – volume: 3 start-page: 455 year: 1972 ident: 323_CR10 publication-title: Res Commun Chem Pathol Pharmacol – volume: 64 start-page: 1147 year: 2008 ident: 323_CR62 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-008-0553-z – volume: 51 start-page: 669 year: 2017 ident: 323_CR20 publication-title: Ann Pharmacother doi: 10.1177/1060028017707541 – ident: 323_CR28 doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 19 start-page: 135 year: 1976 ident: 323_CR45 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1976192135 – volume: 48 start-page: 310 year: 1988 ident: 323_CR63 publication-title: Nephron doi: 10.1159/000184949 – start-page: 333 volume-title: Clinical pharmacokinetics year: 2017 ident: 323_CR38 – volume: 38 start-page: 728 year: 2016 ident: 323_CR51 publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000354 – volume: 18 start-page: 1159 year: 2011 ident: 323_CR75 publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2011.03361.x – volume: 6 start-page: 8 year: 2016 ident: 323_CR12 publication-title: Ment Health Clin doi: 10.9740/mhc.2015.01.008 – ident: 323_CR43 doi: 10.5698/1535-7597.18.4s1.1 – ident: 323_CR70 doi: 10.1517/17425255.2015.1111871 |
SSID | ssj0001368 |
Score | 2.2475028 |
Snippet | Background and objective
Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total... Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total concentrations are... Background and objectivePhenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active, but total... Abstract Background and objective Phenytoin is extensively protein bound with a narrow therapeutic range. The unbound phenytoin is pharmacologically active,... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 343 |
SubjectTerms | Adult Aged Aged, 80 and over Anticoagulants Anticonvulsants - administration & dosage Anticonvulsants - blood Anticonvulsants - pharmacokinetics Binding sites Critical care Drug dosages Drug interactions Drug Monitoring Enzymes Female Humans Internal Medicine Male Medical laboratories Medicine Medicine & Public Health Middle Aged Models, Biological Nonlinear Dynamics Original Original Research Article Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Phenytoin - administration & dosage Phenytoin - blood Phenytoin - pharmacokinetics Plasma Protein Binding Proteins Retrospective Studies Serum Albumin - metabolism Software Therapeutic drug monitoring Young Adult |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQlFegICOhXliLJF7b8bFdsaqQWu2hK_UWJX6IiMpbka3E8l_6X5mxs1mW5wUpp9hxvJ7P488bzzeEvBW20NZyzqxWgsEKZVibi4rljXdF3ihdNfjXwPmFPFtOP16Jqx9SfeGZsCQPnAbuPdemUSa3XilYPI3UGjGqMemOs8579L6w5m03U4MPLngKggO-zURVySFcJgbNwY5JQmdKjKjmJWfl3pIUlft_Rzd_PTX506fTuCLNH5IHA5WkJ-knPCL3XDgkx4ukRb2Z0MtdaFU_ocd0sVOp3jwmd7MxA2FPV57OoTm6QNWGLrDTLga7UMyUdt3T2ajq_A3vAmccG_sMLBVfgE0sQ4tJmqDMhc161QUK1wkKfNBFkm_taTyiQC9WgcEuGGYZPe--OsuSiHKfXgg1npDl_MPl7IwNuRqYAc63ZlLm3DkOfpe3WmL6egCH8B42vU7Ahh1Yi_FKWOMbYaSdttZpaRrnVeVKqMSfkoOwCu45oUoUABcrcs_baeGBE1oDBueN9nxaSZeRYmuu2gxC5phP47oeJZijiWswcR1NXJcZeTc-c5NkPP5a-xRRMNZECe54A4BZD8Cs_wXMjBxtMVQPfqGvwX1yXakqVxl5MxbDjMbPNE1wq9u-BsKlC0yHIjPyLEFu7Ann0FeZVxlRe2Dc6-p-Seg-RdVwJXUB7Dsjky1sd93681C8-B9D8ZLcL3G-xVNAR-Rg_eXWvQIut25fx2n7HXy7RqM priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLam8cIL4k5gICOhvVCjJI7t-AGhraKakDr1YZX2ZiW-QESVQNNJK_-F_8qxc6kKZVKeYsdx4nPs7yQ-34fQO2YSaQylxEjBCKxQmpQxy0lcOJvEhZB54T8NzC_5xTL7cs2uj9Agd9S_wPZgaOf1pJbr1Yfbn9tP4PAfxzQ4iIE4NJ_6HGmaUgJT8j1YmYR31Hm2Yw9PKM_7xJnD1-0tToHD_xDw_Hf_5F8_UcPaNHuIHvSgEp91VvAIHdn6MTpddKzU2wm-2iVZtRN8ihc7vurtE_R7OmoRtrhxeAbN4YXnb6hqcl6FtBfsNdNWLZ6O_M6__FlAj2Nj3wGv-hv4JpZ16eWaoMzW201T1RiOM0_1gRcdkWuLw2YFfNnUBOJh8Dc8r26tIR2dctvdEGo8RcvZ56vpBelVG4gG9LchnMfUWgozMC0l90L2YCbMOQh_LYPQHfCLdoIZ7QqmuclKYyXXhXUitylUos_Qcd3U9gXCgiVgOIbFjpZZ4gAdGh1LQwvpaJZzG6FkGC6le0pzr6yxUiMZcxhiBUOswhCrNELvx2t-dIQed9Y-91Yw1vRk3OFEs_6qet9WVOpC6Ng4IQDfaS6ln0al14WyxjoXoZPBhtRg4AomUipzkcciQm_HYvBt_8OmqG1z0yqAXjLxwig8Qs87kxt7Qin0lcd5hMSeMe51db-krr4F_nDBZQI4PEKTwWx33fr_q3h591O8QvdT70lhp88JOt6sb-xrwGub8k1wwj_eLj5T priority: 102 providerName: Scholars Portal – databaseName: Springer Journals Complete - Open Access dbid: C24 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9swFBajg7GXsXU3b93QYPRlEdhRJFmPbVgog5Q8NNA3Y-uymRV51Cks_S_9rztHvoRs3WDgJ0uWRM5F34l0vkPIR2EzbS3nzGolGOxQhlWpyFlaepelpdJ5iX8NLM_l2Xr25VJc9klh7XDbfTiSjJ56THaDSEfCIFPMhOZTzsDxPhQQu6NezzHHofe_Ge8S4ABrM5Hnsk-VuX-Mve0osvbfBzX_vDH527Fp3I0WT8mTHkbSk07uz8gDFw7Jo2V_UH5IjlcdJfV2Qi92GVbthB7T1Y6sevuc3M3HQoQtbTxdwMh0heQNdWCndcx5oVgw7aql85Hc-RbfAnQcB_sOs-IEOMQ6VFirCdpc2G6aOlB4TpDng646FteWxpsK9LwJDIJhMDa6rH86yzou5babEHq8IOvF54v5GetLNjAD0G_DpEy5cxzcL6-0xCr2oCPCe4h9nYC4HcCL8UpY40thpJ1V1mlpSudV7qbQib8kB6EJ7jWhSmSgNVaknlezzAM0tCbVlpfa81kuXUKyQXKF6fnMsazGVTEyMUdpFyDtIkq7mCbk0_jNj47N45-9T1Ehxp7IxB1fNNdfi96wC65NqUxqvVIA7ozUGn2oxqJQzjrvE3I0qFPRu4e2AC_Kda7yVCXkw9gMho2nNWVwzU1bAO7SGVZFkQl51WnfuBLOYa0yzROi9vRyb6n7LaH-FsnDldQZgPCETAYN3i3r7z_Fm__r_pY8nqKRxWs_R-Rgc33j3gF421Tvo63-An1gPOU priority: 102 providerName: Springer Nature |
Title | Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling |
URI | https://link.springer.com/article/10.1007/s40268-020-00323-2 https://www.ncbi.nlm.nih.gov/pubmed/33026608 https://www.proquest.com/docview/3223987807 https://www.proquest.com/docview/2449181686 https://pubmed.ncbi.nlm.nih.gov/PMC7691416 https://doaj.org/article/39ca7c0df77643c69970309d8cdedeff |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Li9swEBbt7qWX0nfdboMKZS-NqG3ZknUqm7BhKSSEsoHcjK1Ha7rY23UWmv6X_tfOyI5D-lgIhliKPM7MSN_o8Q0h71ITKWM4Z0bJlMEIpVkZphkLC2ejsJAqK3BqYL4QF6vk0zpd9xNubb-tctcn-o7aNBrnyD-A4XGIj7NQfrz-zjBrFK6u9ik07pNjpC7DLV1yPQRcSEeW9Qdl_HE5iJUEiBHjWWoecxYfDEaes_9fQPPv_ZJ_LJr6sWj2iDzsQSQ967T-mNyz9RNyuuxYqLdjerk_VNWO6Sld7vmpt0_Jr-mQe7CljaMzaI4uka-hqtmk8sdcKOZIu2rpdOBz_ol3AS0OjX0DfIoPwCZWdYnpmaDM1ttNU9UUPmdI7UGXHXFrS_3mBLpoagbxL_gXnVc_rGEdfXLbPRBqPCOr2fnl9IL1WRqYBrS3YUKE3FoOPS4vlcDE9WAWqXMQ7toUQnXAK9rJ1GhXpFqYpDRWCV1YJzMbQyX-nBzVTW1fEirTCAzFpKHjZRI5QINGh8rwQjmeZMIGJNqpK9c9hTlm0rjKB_Jlr-IcVJx7FedxQN4Pv7nuCDzurD1BKxhqIvm2v9HcfMl7X8650oXUoXFSAp7TQinsNhXmgbLGOheQk50N5X2P0OZ7-w3I26EYfBkXaIraNrdtDlBLRZgIRQTkRWdygyScg6wizAIiD4zxQNTDkrr66vnCpVAR4O6AjHdmuxfr_3_Fq7vf4jV5EKMn-Z09J-Roc3Nr3wA-25Qj74Qjcjw5Xyw_w7dpnOBVTEd-xgOu8yT7DRTHQFg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4a3QO8IO5kDDAS7IVaJHHjxA8IrWVVx9aqQq20t5D4AtWmZCydoPwX_gK_kePcqnLZ26Q8xY5j5xwfnxP7fB_Ay0B5QinGqBJhQHGFkjR1g4i6idGem4QiSuyvgfGEj-a9DyfByRb8anJh7LHKxiaWhlrl0v4jf4OKxzA-jtzw3flXalmj7O5qQ6FRqcWRXn3DkK14e_ge5fvK94cHs8GI1qwCVKJ3sqScu0xrhhaCpYJbonUcRmAMhmc6wNAS11dpwkBJkwSSq16qtOAy0SaMtI-VGLZ7A7Z7DEOZDmz3DybTj63t9xiP6tScMkEPozOOA_dt9jbzGfU3lr-SJeBfru3fJzT_2KYtV7_hHbhdu61kv9Kzu7Cls3uwN61wr1ddMluncRVdskema0Ts1X34OWjZDguSGzLE5sjUIkQsMtpflIk1xLKynRVk0CJI_7B30T9tGztFj9i-wDYxz1JLCIVlOlst80VG8Nq3YCJkWkHFFqQ8DkEmeUYx4kbRkfHiu1a0AmwuqhdijQcwvxYJPoROlmf6MZAw8FA1VeAalvY8g_6nkq5QLBGG9SKuHfAaccWyBk233B1ncQv3XIo4RhHHpYhj34HX7TPnFWTIlbX7Vgvamhbuu7yRX3yOa-sRMyGTULrKhCF6kJILYQ21sMxTWmljHNhtdCiubVARr2eMAy_aYrQedksoyXR-WcTo3AnPUq9wBx5VKtf2hDHsK3cjB8INZdzo6mZJtvhSIpSHXHjo6TvQbdR23a3_f4qdq0fxHG6OZuPj-PhwcvQEbvl2VpXninahs7y41E_RO1ymz-opSeDTdVuB36rqen8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkBAviG8CA4wEe6HWkrix4weEto5qY6zqwyr1LST-gIopGUsnKP8L_wh_HXdOmqp87G1Sn2LXcXLn81189_sR8jIxkTKGc2aUTBjsUJoVYZKyMHc2CnOp0hw_DRyPxMGk_36aTDfIr2UtDKZVLm2iN9Sm0viNfAcUj0N8nIZyx7VpEeP94duzrwwZpPCkdUmn0ajIkV18g_CtfnO4D7J-FcfDdyeDA9YyDDANnsqcCRFyazlYC14ogaTr8EiJcxCq2QTCTNhrtZOJ0S5PtDD9wlgldG6dTG0MnTiMe41clzyJcI3JaRfsIRRa2hbp-FI9iNMEvIIY67h5zFm8thF6voB_Obl_52r-cWDr98HhbXKrdWDpbqNxd8iGLe-S7XGDgL3o0ZNVQVfdo9t0vMLGXtwjPwcd72FNK0eHMBwdI1bErGR7M19iQ5Gf7bSmgw5L-gdeBU-1G-wL-MZ4AxxiUhZIDQVttlzMq1lJ4beLsCJ03IDG1tQnRtBRVTKIvUFw9Hj23RrWQDfXzQ2hx30yuRL5PSCbZVXaR4TKJAIlNUnoeNGPHHiiRofK8Fw53k-FDUi0FFemW_h0ZPE4zTrgZy_iDESceRFncUBed_85a8BDLu29h1rQ9UTgb3-hOv-UtXYk40rnUofGSQm-pBZKoclWyEFljXUuIFtLHcpaa1Rnq7UTkBddM9gRPBzKS1td1Bm4eSpCEhYRkIeNynUz4RzmKsI0IHJNGdemut5Szj57rHIpVAQ-f0B6S7VdTev_r-Lx5U_xnNyAtZ99OBwdPSE3Y1xUPsFoi2zOzy_sU3AT58Uzvx4p-XjVBuA33Gt9Tw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparisons+of+Four+Protein-Binding+Models+Characterizing+the+Pharmacokinetics+of+Unbound+Phenytoin+in+Adult+Patients+Using+Non-Linear+Mixed-Effects+Modeling&rft.jtitle=Drugs+in+R%26D&rft.au=Jun%2C+Heajin&rft.au=Rong%2C+Yan&rft.au=Yih%2C+Catharina&rft.au=Ho%2C+Jordan&rft.date=2020-12-01&rft.pub=Springer+Nature+B.V&rft.eissn=1179-6901&rft.volume=20&rft.issue=4&rft.spage=343&rft.epage=358&rft_id=info:doi/10.1007%2Fs40268-020-00323-2&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1174-5886&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1174-5886&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1174-5886&client=summon |